CDXS earnings analysis
What we found in CDXS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Codexis delivered mixed Q2 results: revenue declined 3% year over year to $14.915 million because a 79% increase in product revenue was more than offset by a 79% decline in R&D revenue. Product gross margin improved to 73%, operating expenses fell 7%, and diluted EPS improved to a $0.13 loss, but the company remains substantially loss-making and used $22.793 million of operating cash in the first half. Liquidity was reinforced by approximately $23.1 million of post-quarter public-offering proceeds, although cash declined to $27.172 million at quarter-end and debt principal was $40.0 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Product growth offset R&D revenue decline
- Q2 revenue was $14.915 million, down $0.413 million, or 3%, from $15.328 million in Q2 2025. Product revenue increased 79% to $13.218 million, offset by a 79% decline in R&D revenue to $1.697 million.
- Product gross margin improved to 73%
- Product gross margin improved to 73% from 72% in Q2 2025, which management attributed to a shift toward more profitable products and declines in less profitable legacy products.
- Operating loss and EPS improved
- Loss from operations narrowed to $11.229 million from $12.862 million, while net loss narrowed to $12.005 million from $13.272 million. Diluted EPS improved to a $0.13 loss from a $0.16 loss.
- Cost reductions continued
- Operating expenses declined 7% to $26.144 million. R&D expense decreased 15% to $11.705 million and SG&A decreased 11% to $10.927 million, primarily due to lower headcount and related costs.
- Operating cash burn improved
- Cash used in operating activities was $22.793 million for the first six months, an improvement from $31.765 million in the prior-year period. Investing cash flow was an outflow of $0.936 million, with management noting reduced capital expenditures.
- ECO GMP facility moves toward construction
- The company applied for a building permit during Q2 2026 and expects retrofit construction for its 34,000-square-foot ECO GMP Manufacturing Center to begin during the second half of 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent losses and accumulated deficit
- The company reported a $20.709 million net loss for the first six months and had an accumulated deficit of $627.5 million at June 30, 2026. Management expects significant operating expenses and net losses to continue as it develops and commercializes ECO Synthesis.
- Liquidity and debt burden
- Cash and cash equivalents fell to $27.172 million from $50.793 million at December 31, 2025, while six-month operating cash use was $22.793 million. The company also had $40.0 million of Innovatus principal outstanding plus $1.6 million of accrued payment-in-kind interest.
- Customer concentration increased
- Customers contributing at least 10% individually represented 60% of total revenue for the six months ended June 30, 2026, versus 43% in the prior-year period, increasing exposure to customer losses, order timing and contract renewals.
- ECO GMP execution and scale-up risk
- The company currently does not manufacture GMP-grade products at its own facilities and remains reliant on third-party CDMOs. Retrofit construction of the 34,000-square-foot ECO GMP Manufacturing Center is expected to begin only in the second half of 2026.
- BIOSECURE Act supply-chain exposure
- The filing newly highlights the U.S. BIOSECURE Act, enacted in December 2025, and notes that existing contracts have a five-year grandfathering period. Future restrictions could affect counterparties and foreign manufacturing relationships.
- Cybersecurity and AI-related risk
- The filing expands discussion of AI-related cybersecurity exposure, noting that attacks may use AI tools and that the company has received phishing emails and phone calls seeking sensitive information. A significant breach could disrupt operations and cause liability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.13
- Gross margin
- 73%
- Segment
- Product revenue: $13.218 million, up 79% year over year; six-month revenue was $20.409 million, up 52%.
- Segment
- Research and development revenue: $1.697 million, down 79% year over year; six-month revenue was $9.754 million, up 3%.
- Segment
- Total revenue: $14.915 million, down 3% year over year; six-month revenue was $30.163 million, up 32%.
What they said about what is next.
The 10-Q provides no explicit numeric revenue or EPS guidance. Management states that existing cash, cash equivalents, future revenue expectations and expense management should fund planned operations, capital expenditures and working capital requirements for at least the next 12 months.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Codexis reported a strong performance for Q1 2026, with revenue of $15.2 million, an increase of 102% compared to the prior year. The company's gross margin improved significantly to 71%, up from 55% a year earlier,…
- 10-K · March 11, 2026
- Codexis describes a two-pronged strategy: grow its small-molecule pharma biocatalysis business while commercializing the ECO Synthesis enzymatic RNA manufacturing platform via partnerships and its Innovation Lab. Fiscal…
- 10-Q · November 6, 2025
- Codexis reported Q3 revenue of $8.60M, down from $12.83M in the year-ago quarter, with GAAP net loss of $19.615M and diluted loss per share of $(0.22). Product revenue declined materially while R&D revenue was slightly…
- 10-Q · August 13, 2025
- Codexis reported Q2 revenue of $15.33M (three months ended June 30, 2025) vs $7.98M a year ago, driven by a $4.70M milestone and higher R&D revenue; GAAP loss per share improved to $(0.16) from $(0.32). Operating loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CDXS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever